^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Neofordex (dexamethasone acetate high-dose)

    Associations

    News

    Trials
    Company:
    CTRS Laboratories, Zaphyr Pharma
    Drug class:
    GCR agonist
    Related drugs:
    Associations

    News

    Trials
    9ms
    A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma (clinicaltrials.gov)
    P2, N=96, Suspended, Hackensack Meridian Health | Trial completion date: Jan 2025 --> Jan 2026 | Recruiting --> Suspended | Trial primary completion date: Jan 2025 --> Jan 2026
    Trial completion date • Trial suspension • Trial primary completion date
    |
    Xpovio (selinexor) • Darzalex (daratumumab) • carfilzomib • dexamethasone • pomalidomide • Neofordex (dexamethasone acetate high-dose)
    12ms
    FREEDOM: Study Comparing Therapy for Advanced Relapsed/Refractory Multiple Myeloma With and Without Dexamethasone (clinicaltrials.gov)
    P3, N=318, Recruiting, Assistance Publique - Hôpitaux de Paris | Not yet recruiting --> Recruiting
    Enrollment open • Head-to-Head • Metastases
    |
    carfilzomib • dexamethasone • Neofordex (dexamethasone acetate high-dose)
    over1year
    FREEDOM: Study Comparing Therapy for Advanced Relapsed/Refractory Multiple Myeloma With and Without Dexamethasone (clinicaltrials.gov)
    P3, N=318, Not yet recruiting, Assistance Publique - Hôpitaux de Paris
    New P3 trial • Head-to-Head • Metastases
    |
    carfilzomib • dexamethasone • Neofordex (dexamethasone acetate high-dose)
    over1year
    SABLe: Selinexor With Alternating Bortezomib or Lenalidomide Plus Dexamethasone in TIE Newly Diagnosed MM Patients (clinicaltrials.gov)
    P2, N=50, Active, not recruiting, Ida Bruun Kristensen | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    lenalidomide • bortezomib • Xpovio (selinexor) • dexamethasone • Neofordex (dexamethasone acetate high-dose)
    almost2years
    A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma (clinicaltrials.gov)
    P2, N=96, Recruiting, Hackensack Meridian Health | Phase classification: P2b --> P2 | Trial completion date: Jan 2024 --> Jan 2025 | Trial primary completion date: Jan 2024 --> Jan 2025
    Phase classification • Trial completion date • Trial primary completion date • Combination therapy
    |
    Xpovio (selinexor) • Darzalex (daratumumab) • carfilzomib • dexamethasone • pomalidomide • Neofordex (dexamethasone acetate high-dose)
    over2years
    SABLe: Selinexor With Alternating Bortezomib or Lenalidomide Plus Dexamethasone in TIE Newly Diagnosed MM Patients (clinicaltrials.gov)
    P2, N=50, Recruiting, Ida Bruun Kristensen | N=100 --> 50
    Enrollment change
    |
    lenalidomide • bortezomib • Xpovio (selinexor) • dexamethasone • Neofordex (dexamethasone acetate high-dose)